Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 122 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Tissue Adhesion Clear all
Completed Phase 2 Interventional

Stem Cell Transplantation to Treat Leukocyte Adhesion Deficiency

NCT00031005
View directory record Official record
Conditions
Leukocyte-Adhesion Deficiency Syndrome
Interventions
modified stem cell transplant
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 9:12 AM EDT
Completed Phase 1 Interventional

Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer

NCT01778803
View directory record Official record
Conditions
Ovarian Cancer
Interventions
defactinib, Paclitaxel
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Jul 22, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Results available

AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis

NCT04897594
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-201, Placebo
Drug · Other
Lead sponsor
Terns, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Tucson, Arizona • Coronado, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Jul 22, 2026, 9:12 AM EDT
Terminated Phase 1 Interventional

Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects

NCT02651727
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine, Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine, Part A- VS-4718, nab-paclitaxel, gemcitabine
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
St Louis, Missouri • Gettysburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Jul 22, 2026, 9:12 AM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Juveena™ Hydrogel System Following Transcervical Gynecologic Procedures (TCGP) At High-Risk for Intrauterine Adhesions

NCT05394662
View directory record Official record
Conditions
Intrauterine Adhesion
Interventions
Juveena Hydrogel System, Transcervical Gynecologic Procedures (TCGP)
Device · Procedure
Lead sponsor
Rejoni Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
15
States / cities
Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 22, 2026, 9:12 AM EDT
Recruiting Not applicable Interventional

Intrauterine Stent Placement Following Hysteroscopic Septum Resection

NCT07032506
View directory record Official record
Conditions
Intrauterine Adhesion
Interventions
Intraoperative placement of an inflated intrauterine pediatric foley catheter, No Catheter placement, Hormonal Therapy Agent, Oral antibiotics
Procedure · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Little Rock, Arkansas • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 9:12 AM EDT
Terminated Not applicable Interventional

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

NCT00006054
View directory record Official record
Conditions
Immunologic Deficiency Syndromes, Chediak-Higashi Syndrome, Common Variable Immunodeficiency, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, X-linked Hyper IgM Syndrome, Severe Combined Immunodeficiency, Leukocyte Adhesion Deficiency Syndrome, Virus-Associated Hemophagocytic Syndrome
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, etoposide, methotrexate, methylprednisolone, prednisone, Allogeneic Bone Marrow Transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
Up to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2009 · Synced Jul 22, 2026, 9:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of Adhesion and Dermal Tolerability of EMSAM

NCT00531596
View directory record Official record
Conditions
Healthy
Interventions
EMSAM (Selegiline Transdermal System) 6mg/24Hr, EMSAM (Selegiline Transdermal System) 9mg/24Hr, EMSAM (Selegiline Transdermal System) 12mg/24hr
Drug
Lead sponsor
Somerset Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Scottsdale, Arizona • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2007 · Synced Jul 22, 2026, 9:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Compare Effect of Surgical Antiseptic Preparations on Incise Drape Adhesion to Skin

NCT01290978
View directory record Official record
Conditions
Healthy
Interventions
ChloraPrep, DuraPrep
Drug
Lead sponsor
Solventum US LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Jul 22, 2026, 9:12 AM EDT
Completed Phase 3 Interventional Results available

Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.

NCT00798317
View directory record Official record
Conditions
Vitreomacular Adhesion
Interventions
Ocriplasmin 125µg, Placebo
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
20
States / cities
Campbell, California • San Francisco, California • Santa Barbara, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Jul 22, 2026, 9:12 AM EDT
Completed No phase listed Observational

Hemoglobin Desaturation in Sickle Cell Disease

NCT03908385
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Jul 22, 2026, 9:12 AM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Raptiva to Treat Sjogren's Syndrome

NCT00344448
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Raptiva
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Jul 22, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Lidocaine Patch 5% and Lidocaine Medicated Plaster 5% in Healthy, Adult, Human Subjects

NCT04320173
View directory record Official record
Conditions
Healthy
Interventions
Lidocaine patch 1.8%, Lidocaine patch 5%, Lidocaine medicated plaster 5%
Drug
Lead sponsor
Scilex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Jul 22, 2026, 9:12 AM EDT
Completed Not applicable Interventional Results available

Vitamin D Repletion in Coronary Artery Disease

NCT01570309
View directory record Official record
Conditions
Vitamin D Deficiency, Coronary Artery Disease, Endothelial Dysfunction, Inflammation
Interventions
Ergocalciferol, Sugar pill
Drug · Other
Lead sponsor
Seth I. Sokol, M.D.
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Jul 22, 2026, 9:12 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Characterizing PAI-1 Modulation on Monocyte Adhesion

NCT00512031
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 17, 2011 · Synced Jul 22, 2026, 9:12 AM EDT
Withdrawn Not applicable Interventional

An Adhesion Reduction Plan in the Management of the Surgical Open Abdomen

NCT01010464
View directory record Official record
Conditions
Open Abdomen
Interventions
Adhesion Reduction Plan
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2020 · Synced Jul 22, 2026, 9:12 AM EDT
Completed No phase listed Observational

A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA

NCT02193945
View directory record Official record
Conditions
Symptomatic Vitreomacular Adhesion (VMA)
Interventions
Not listed
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Campbell, California • La Jolla, California • Santa Ana, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Jul 22, 2026, 9:12 AM EDT
Terminated Phase 1 Interventional

A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma

NCT02372227
View directory record Official record
Conditions
Relapsed Malignant Mesothelioma
Interventions
VS-5584 and VS-6063
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Jul 22, 2026, 9:12 AM EDT
Withdrawn Phase 1 Interventional

Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration

NCT00726466
View directory record Official record
Conditions
Age Related Macular Degeneration, AMD, CNV
Interventions
Efalizumab, Ranibizumab
Drug
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2015 · Synced Jul 22, 2026, 9:12 AM EDT
Completed Phase 1 Interventional

Bone Marrow Transplant With Abatacept for Non-Malignant Diseases

NCT01917708
View directory record Official record
Conditions
Hurler Syndrome, Fanconi Anemia, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Shwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia, Thalassemia Major, Hemophagocytic Lymphohistiocytosis, Sickle Cell Disease
Interventions
Abatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Jul 22, 2026, 9:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Composition of Dental Plaque

NCT00001726
View directory record Official record
Conditions
Dental Caries, Dental Plaque, Periodontal Disease
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 9:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Physical Therapy in Addition to Standard Care Following C-Section

NCT02804139
View directory record Official record
Conditions
Low Back Pain, Pelvic Pain, Scar Tissue, Adhesions
Interventions
Standard care plus physical therapy, Standard Care
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Jul 22, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy Subjects

NCT07571824
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
Selegiline TDS 6 mg/24 hours, EMSAM® TDS 6 mg/24 hours
Drug
Lead sponsor
Corium Innovations, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 9:12 AM EDT
Completed No phase listed Observational

Ocriplasmin Research to Better Inform Treatment (ORBIT)

NCT02079883
View directory record Official record
Conditions
Symptomatic Vitreomacular Adhesion
Interventions
Not listed
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
110
States / cities
Phoenix, Arizona • Beverly Hills, California • Encino, California + 92 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Jul 22, 2026, 9:12 AM EDT